Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - MicardisPlus(R) - Hypertonie (38 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 29: Blutdrucksenkung - Through/Peak-Ratio Abb. 30: Hypertonie - Behandlung Abb. 31: Hypertonie - Behandlung Aktuelles Bild - Abb. 32: Antihypertensiva - Nebenwirkung Abb. 33: Hypertonie - Behandlung Abb. 34: Antihypertensiva- Eigenschaften Abb. 35: Hypertonie - Behandlung - Richtlinien Zum letzten Bild
Abbildung 32: Antihypertensiva - Nebenwirkung
Another common reason for poor patient adherence is side effects. Because hypertension is largely asymptomatic, and because treatment can often last years or decades, good tolerability is essential. This slide lists some of the side effects commonly associated with widely used antihypertensive classes.1 1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1–S266.
 
Antihypertensiva - Nebenwirkung
Vorheriges Bild Nächstes Bild   


Abbildung 32: Antihypertensiva - Nebenwirkung
Another common reason for poor patient adherence is side effects. Because hypertension is largely asymptomatic, and because treatment can often last years or decades, good tolerability is essential. This slide lists some of the side effects commonly associated with widely used antihypertensive classes.1 1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1–S266.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung